Summary
The lectin pathway of complement is activated by complexes comprising a recognition component (mannose-binding lectin, serum ficolins, collectin-LK or collectin-K1) and a serine protease (MASP-1 or MASP-2). MASP-1 activates MASP-2, and MASP-2 cleaves C4 and C4b-bound C2. To clarify activation, new crystal structures of Ca2+-bound MASP dimers were determined, together with their solution structures from X-ray scattering, analytical ultracentrifugation, and atomistic modeling. Solution structures of the CUB1-EGF-CUB2 dimer of each MASP indicate that the two CUB2 domains were tilted by as much as 90° compared with the crystal structures, indicating considerable flexibility at the EGF-CUB2 junction. Solution structures of the full-length MASP dimers in their zymogen and activated forms revealed similar structures that were much more bent than anticipated from crystal structures. We conclude that MASP-1 and MASP-2 are flexible at multiple sites and that this flexibility may permit both intra- and inter-complex activation.
Keywords: analytical ultracentrifugation, complement, atomistic modeling, lectin pathway, rat MASP, X-ray scattering
Highlights
-
•
Ca2+-bound MASP crystal structures reveal binding sites for MBL and other ligands
-
•
The MASP crystal structures predict linear domain structures
-
•
Solution structures of MASP-1 and MASP-2 are bent by as much as 90° from linearity
-
•
Flexibility in MASP dimers may permit both intra- and inter-complex activation
Nan et al. show that MASPs, the serine proteases responsible for initiating the lectin pathway of complement activation, are much more flexible in solution than previously thought. This flexibility probably facilitates both intra- and inter-complex activation when mannan-binding lectin-MASP complexes bind to pathogen surfaces.
Introduction
Complement destroys invading microorganisms and initiates defense mechanisms including chemotaxis, phagocytosis, cell adhesion, B cell differentiation, and maintenance of immune tolerance (Carroll, 2004, Porter and Reid, 1978). It also facilitates tissue remodeling, homeostasis, and resolution of inflammation via apoptosis and clearance of cellular debris (Botto, 1998, Taylor et al., 2000). Defects in complement are associated with immunodeficiencies, autoimmune diseases, tissue damage, anaphylaxis, transplant rejection, and necrosis. Complement via the lectin pathway is initiated when mannan-binding lectin (MBL), serum ficolins, collectin-KL, and/or collectin-K1 bind to pathogens and activate MBL-associated serine proteases (MASP-1 and MASP-2 and MASP-3) (Figure 1). The importance of the lectin pathway is highlighted by common immunodeficiencies associated with mutations to MBL (Turner, 1996) and MASP-2 (Stengaard-Pedersen et al., 2003). Inappropriate lectin pathway activation causes tissue damage following transient ischemia (Schwaeble et al., 2011), so modulators of the lectin pathway are likely to have important therapeutic benefits.
MBLs are large oligomers (150–300 kDa), predominantly dimers to tetramers of a homotrimeric subunit (Wallis and Drickamer, 1999). In each homotrimer, pathogen recognition is mediated through the coordinated binding of three globular carbohydrate recognition domains (CRDs) connected to a rod-like collagenous stem (Figure 1). MASPs are homodimers that circulate as zymogens bound to the collagenous domains of MBL (Wallis and Dodd, 2000). Each MASP comprises two N-terminal CUB (C1r/C1s, Uegf, and bone morphogenetic protein-1) domains separated by an epidermal growth factor (EGF)-like domain followed by two short complement regulator (SCR) domains and a C-terminal serine protease (SP) domain (Figure 1). MASP-1 and MASP-3 are alternatively spliced products from the same gene. Activation occurs following cleavage at a single site between the SCR2 and SP domains when MBLs bind to a pathogen surface. MASP-1 cleaves MASP-2, which subsequently cleaves the downstream complement components C4 and C4-bound C2 to form the C3 convertase (Wallis et al., 2007). MASP-1 and/or MASP-3 facilitate activation of the alternative pathway through activation of factors D and B (Iwaki et al., 2011, Takahashi et al., 2010). It is often assumed that the MBLs adopt bouquet-like structures similar to complement C1q. Instead, our recent atomistic scattering modeling showed that they have near-planar, fan-shaped structures in solution (Figure 1), which raises new questions on how the complexes activate complement (Miller et al., 2012). In two different theories following attachment of the MBL-MASP complex to a pathogenic surface, either (1) each monomer within the MASP dimer is able to bend significantly to enable one SP domain to activate its partner, as occurs for the MASP homologs, C1r and C1s within the C1 complex, or (2) a given MASP-MBL complex activates neighboring MASP molecules on adjacent MBL-MASP complexes (Degn et al., 2014, Wallis et al., 2010). A recent analysis by small- angle X-ray scattering (SAXS) and electron microscopy (EM) favored the inter-complex model, concluding that MASP-1 was only modestly flexible and the protease domains were too far apart to enable intra-complex activation (Kjaer et al., 2015).
Here, we investigate the dimer structures of MASP-1 and MASP-2 through the combination of SAXS, analytical ultracentrifugation (AUC), and a new atomistic modeling procedure (Perkins et al., 2011, Perkins et al., 2016). While several crystal structures are known for the N-terminal MASP fragments (Feinberg et al., 2003, Gingras et al., 2011, Gregory et al., 2004, Skjoedt et al., 2012, Teillet et al., 2006) and for the C-terminal MASP fragments (Dobo et al., 2009, Gal et al., 2005, Harmat et al., 2004, Heja et al., 2012, Kidmose et al., 2012), these are incomplete. In particular, MASP-2 CUB1-EGF-CUB2 (subsequently called MASP-2 3D) was crystallized in the presence of citrate that chelates Ca2+, and although Ca2+ was bound to the EGF-like domain, the CUB1 and CUB2 domains lacked Ca2+ and became partially disordered as a result (Feinberg et al., 2003). Here, to complete our knowledge of the MASP structures, we first applied X-ray crystallography to the N-terminal fragments to identify the importance of bound Ca2+. Next, by applying our strategy to the zymogen and activated forms of MASP, we assessed whether the MASP dimer is sufficiently flexible to allow auto-activation or inter-molecular activation.
There are four potential binding sites for MBL stems on each MASP homodimer—one on each of the four CUB domains (Wallis and Dodd, 2000; Figure 1). The crystal structures of collagen-like peptides bound to CUB1 and CUB2 mean we now know the MBL-MASP contacts at atomic resolution (Gingras et al., 2011, Venkatraman Girija et al., 2013). These structures reveal key contacts between an essential Lys46 residue in the collagen-like region of MBL and three Ca2+-binding residues in CUB2. The Ca2+-binding site is conserved in CUB1, which binds to a separate collagen stem. By comparing the MASP solution structures with models for MBL, we evaluated the MASP-MBL complexes that trigger complement activation. In particular, our new MASP structures clarify the extent to which the MASPs undergo significant conformational changes during activation after pathogen binding by MBL.
Results
Purification and Crystal Structure Determination of MASPs
Following the crystallography and scattering strategy used for rat MBL (Miller et al., 2012), we expressed full-length rat MASP-1 and MASP-2 zymogens and both their 3D fragments for structural analysis (Figure 1). Repeated attempts to obtain diffracting crystals of full-length MASP-1 and MASP-2 were unsuccessful, probably due to inter-domain flexibility. An alternative strategy involving crystallography of MASP fragments was followed. Because there was no structure of rat MASP-1 3D, and the existing structure of rat MASP-2 3D lacked two of the three Ca2+, including those Ca2+ that form part of the binding site for MBL, both rat MASP-1 3D and MASP-2 3D were crystallized in the presence of 2 mM calcium and diffraction data were collected. This resulted in one MASP-1 structure at 3.7 Å resolution and three independent MASP-2 structures at 2.6–2.7 Å resolution (Table 1).
Table 1.
MASP-2 MPD/Acetate | MASP-2 PEG 20K | MASP-2 MPD/Citrate | MASP-1 | |
---|---|---|---|---|
Data Collection | ||||
Beamline | Diamond I04-1 | Diamond I04-1 | Cu2+ home source | Diamond I04 |
Space group | P 21 21 21 | C 2 2 21 | C 2 2 21 | I 2 3 |
a, b, c (Å) | 83.6, 91.3, 127.1 | 66.9, 98.3, 121.4 | 82.9, 119.4, 104.0 | 152.7, 152.7, 152.7 |
α, β, γ, ° | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 |
Resolution (Å) | 63.6–2.6 (2.69–2.60) | 50.3–2.58 (2.60–2.58) | 22.9–2.73 (2.82–2.73) | 76.4–3.70 (4.14–3.70) |
Rsym | 0.082 (0.321) | 0.099 (0.645) | 0.167 (0.653) | 0.082 (0.743) |
I/σ(I) | 16.04 (2.10) | 11.55 (2.03) | 6.4 (1.53) | 9.2 (1.51) |
Completeness | 97.6 (98.8) | 97.6 (93.5) | 99.4 (94.4) | 99.9 (99.9) |
Redundancy | 5.0 (5.2) | 3.9 (3.6) | 2.0 (2.0) | 5.6 (5.5) |
Refinement | ||||
Resolution (Å) | 63.55–2.6 (2.69–2.60) | 50.34–2.58 (2.67–2.58) | 22.9–2.73 (2.82–2.73) | 76.4–3.70 (3.84–3.70) |
No. of reflections | 29,893 (2,998) | 12,626 (1,195) | 14,031 (1,319) | 6,473 (1827) |
Rwork/Rfree | 0.205/0.254 | 0.207/0.245 | 0.204/0.266 | 0.248/0.294 |
No. of atoms | 4,502 | 2,303 | 2,369 | 2,271 |
Protein | 4,433 | 2,208 | 2,211 | 2,239 |
Ligand/ion | 6 | 17 | 17 | 32 |
Water | 63 | 78 | 141 | – |
B factors (Å2) | 93.40 | 51.60 | 34.70 | 187.20 |
Protein | 93.90 | 51.70 | 35.00 | 187.60 |
Ligand/ion | 65.80 | 78.20 | 65.90 | 155.50 |
Water | 62.30 | 44.30 | 26.80 | – |
PDB | 5CKN | 5CIS | 5CKM | 5CKQ |
RMSDs | ||||
Bond lengths (Å) | 0.004 | 0.003 | 0.004 | 0.002 |
Bond angles (°) | 1.01 | 0.72 | 0.82 | 0.75 |
Ramachandran (%) | ||||
Favored | 94 | 93 | 94 | 92 |
Allowed | 6 | 7 | 6 | 8 |
Disallowed | 0 | 0 | 0 | 0 |
The buffers are defined in full in the Supplemental Information. The highest resolution shell is shown in parentheses.
The four electron density maps were of high quality (Figure S1). For MASP-1 3D, 276 of its 281 residues could be built into the electron density map. The resulting structure was similar to the corresponding structure of human MASP-1 (PDB: 3DEM), with a root-mean-square deviation (RMSD) of 0.961 Å over 267 residues (Teillet et al., 2008). For MASP-2 3D, 279 of 280 residues were visible. Interestingly, the three structures overlaid closely, with RMSDs of 0.682, 0.871, and 0.992 Å over 276 Cα atoms. The only notable differences were in the N-terminal seven residues and in a loop within the EGF-like domain (Thr125–Ser130), probably reflecting flexibility. All three MASP-2 3D structures were similar to the previous structure of rat MASP-2 3D (PDB: 1NT0) with RMSDs of 1.20, 1.35, and 1.57 Å over 257 Cα atoms (Feinberg et al., 2003). A major difference, however, was that the structures now contained three bound Ca2+ compared with the single Ca2+ in the EGF-like domain of the earlier MASP-2 3D structure. Each CUB domain bound one Ca2+, where the Ca2+-binding residues and binding loops were well defined. These Ca2+ sites are functionally important because they orientate and form the binding site for MBL, ficolins, CL-KL, and CL-K1 (Gingras et al., 2011). All four crystal structures revealed a dimer of MASP-1 3D or MASP-2 3D, formed by antiparallel neighboring contacts between pairs of CUB1-EGF domains about the crystallographic symmetry axis (Figures 2A and 2B). The same dimer was seen in earlier crystal structures of MASPs (PDB: 1NT0 and 3DEM), further supporting earlier conclusions that this is physiologically relevant (Feinberg et al., 2003, Gregory et al., 2003, Skjoedt et al., 2012, Teillet et al., 2008). The total buried surface area for MASP-1 at the dimer interface was 880 Å2 per molecule (1,760 Å2 in total), whereas the three crystal structures for MASP-2 gave 1,200, 1,090, and 950 Å2 per molecule. These values were in excess of 800 Å2, consistent with stable dimer formation (Rupp, 2010).
Bioavailable calcium is typically present in plasma at around 2.5 mM (Hurwitz, 1996). All four new crystal structures revealed well-ordered, similar calcium-binding sites in each of the CUB1 and CUB2 domains (Figures 2A and 2B). These were previously seen for human MASP-1 3D, but not for rat MASP-2 3D (Figures 2C and 2D). In the MASP-1 CUB1 domain, Ca2+ formed contacts with six oxygen atoms in the side chains of Glu49, Asp57, Asp102, Ser104, and Asn105 (distances between 2.3 and 2.4 Å). In the MASP-2 CUB1 domain, Ca2+ formed contacts with six oxygen atoms in the side chains of Glu48, Asp56, Asp101, and Asn104 and the main chain oxygen of Ser103 (distances between 2.3 and 2.7 Å; Figure S1A). In the MASP-1 CUB2 domain, Ca2+ now formed contacts with five oxygen atoms in the structurally equivalent side chains of Glu216, Asp226, Asp263, and Ser265. In the MASP-2 CUB2 domain, Ca2+ formed contacts with five oxygen atoms at the side chains of Glu215, Asp225, Asp262, and Ser264 (Figure S1B). This second site differed from that in CUB1 only by the omission of the side chain with the structurally equivalent Asn105/Asn104 oxygen atom in CUB2. Nonetheless, this Ca2+ site was similar to that reported in the CUB2 domain of MASP-1 alone (Gingras et al., 2011). Comparison of the same CUB1/CUB2 region in the earlier crystal structure of rat MASP-2 showed disorganized binding loops in the absence of calcium (Figure 2D), suggesting that Ca2+ stabilizes the MBL-binding residues. The EGF domains of MASP-1 and MASP-2 also bound calcium (Figures 2C and 2D).
X-Ray Scattering of Rat MASPs
X-ray scattering measures by diffraction the overall structure of biological molecules in randomized orientations in solution (Perkins et al., 2011). Here, solution scattering identified the domain structures of MASP-1 3D, MASP-2 3D, MASP-1 zymogen/activated, and MASP-2 zymogen/activated, with and without Ca2+, in order to verify the structures seen by crystallography. The scattering data I(Q) were collected at concentrations dilute enough to minimize concentration effects (0.25–1.36 mg/mL). The MASPs showed no radiation damage or X-ray induced aggregation in the time frame analyses. The time-averaged runs were thus used for data analyses. Guinier analyses of the I(Q) data in two separate Q ranges gave the radius of gyration Rg and the cross-sectional radius of gyration Rxs (Figure 3).
The Rg value monitors the overall degree of elongation of the MASP dimers. At the lowest Q values, the Rg values were measured within satisfactory Q.Rg limits in concentration series between 0.25 and 1.26 mg/mL for the six MASPs (Figure 3A). The mean of two to four Rg values were 3.83 ± 0.02 nm for MASP 3D and 7.73 ± 0.20 nm for full-length MASP (Table 2). The Rg values for the full-length MASPs were almost double those of the MASP 3Ds, this being as expected if the full-length MASPs have extended six-domain structures. No change with protein concentrations in either the I(0)/c or Rg values for each of the six MASPs was observed. This meant that no self-association or conformational change in MASP was detectable with change in protein concentration. No change between the pairs of Rg values for zymogen and activated MASP-1 and MASP-2 was seen (Table 2), indicating that their domain arrangements were unaffected by cleavage of the SCR2-SP linker.
Table 2.
Rg (nm)a | Rxs (nm) | L (nm) | s20,w (S)b | |
---|---|---|---|---|
Experimental | ||||
MASP-1 3D (12 curves) | 3.79 ± 0.01 3.97 ± 0.01 |
1.94 ± 0.01 | 13 | 4.53 ± 0.08 |
MASP-2 3D (9 curves) | 3.87 ± 0.02 3.99 ± 0.01 |
1.74 ± 0.02 | 12 | 4.09 ± 0.07 |
Zymogen MASP-1 (14 curves) | 7.93 ± 0.09 8.23 ± 0.02 |
1.54 ± 0.02 | 26 | 5.90 ± 0.15 |
Activated MASP-1 (8 curves) | 7.86 ± 0.12 8.22 ± 0.02 |
1.53 ± 0.02 | 26 | 5.79 ± 0.13 |
Zymogen MASP-2 (9 curves) | 7.58 ± 0.13 7.98 ± 0.02 |
1.46 ± 0.06 | 27 | 5.42 ± 0.15 |
Activated MASP-2 (4 curves) | 7.54 ± 0.04 7.79 ± 0.04 |
1.46 ± 0.05 | 26 | 5.62 ± 0.16 |
Best-Fit Models | ||||
MASP-1 3D | 3.79 ± 0.09 | 1.93 ± 0.03 | 14.1 ± 0.7 | 4.25 ± 0.07 |
MASP-2 3D | 3.92 ± 0.07 | 1.89 ± 0.33 | 14.3 ± 0.5 | 3.96 ± 0.03 |
Zymogen MASP-1 | 7.73 ± 0.17 | 1.71 ± 0.06 | 26.4 ± 0.9 | 5.92 ± 0.05 |
Activated MASP-1 | 8.09 ± 0.23 | 1.67 ± 0.10 | 25.1 ± 1.2 | 5.92 ± 0.07 |
Zymogen MASP-2 | 7.34 ± 0.27 | 1.32 ± 0.22 | 23.5 ± 1.0 | 5.69 ± 0.10 |
Activated MASP-2 | 7.70 ± 0.18 | 1.49 ± 0.10 | 25.3 ± 1.1 | 5.61 ± 0.10 |
The cross-sectional Rxs Guinier analyses monitored the shorter dimensions of the MASP dimers. The ln I(Q).Q versus Q2 plots showed linear regions in the 3D and full-length proteins (Figure 3B), indicating that both proteins were elongated. The resulting Rxs values for MASP-1 3D and MASP-2 3D were similar at 1.94 ± 0.01 nm and 1.74 ± 0.02 nm, respectively (Table 2). For the full-length zymogen and activated MASP, the four I(Q).Q versus Q2 plots showed inflexions before a linear Rxs region, indicating complex but similar domain arrangements in MASPs. The resulting Rxs values were indistinguishable for zymogen and activated MASP-1 (at 1.53–1.54 nm) and MASP-2 (both at 1.46 nm). This indicated no major conformational differences between the zymogen and activated forms, even with the addition or removal of Ca2+. The similar Rxs values for MASP-1 and MASP-2 indicated that both showed similar cross-sectional structures.
The distance distribution function P(r) represented all the distances between pairs of atoms within the macromolecule. This provided structural information in real space. The P(r) curve provided an alternative calculation of the Guinier Rg value and gave maximum lengths (L) following an assumption of the maximum dimension (Dmax). The Rg values from P(r) were similar to those from the Guinier analyses as expected (Table 2). The maximum length L of the MASPs was determined from the r value when P(r) = 0 at large r (Figure 4C). For both 3D MASPs, a single peak was observed in P(r) with the most common intra-particle distance at a maximum M of 3.9 nm and a length L of 13 nm. This M value corresponds well to the mean intra-domain distance within the four CUB domains. For zymogen and activated full-length MASP, two peaks M1 and M2 at 3.4 nm and 10.7 nm, respectively, were seen. M1 was assigned to structures similar to those in MASP 3D. M2 corresponded well to the distances between the two SP domains and the CUB domains in the center of the MASP dimer.
Analytical Ultracentrifugation of Rat MASPs
AUC studies solution structures by monitoring their sedimentation under high centrifugal force (Cole et al., 2008). This provided information on the structure and oligomerization of MASP. The latter was important because the MASPs were purified in low 20 mM NaCl salt, which may promote oligomer formation. Sedimentation velocity experiments were performed on the six MASPs at concentrations similar to those used for SAXS in physiological ionic strength conditions in the same buffers with Ca2+ or EDTA (Figures 4A and 4E). The velocity data were analyzed using absorbance optics to generate the size distribution analyses c(s). The analyses of up to 80 boundaries revealed excellent fits and satisfactory RMSDs. The mass determination from the single c(s) peak showed that all six samples were dimers with no detectable monomer or higher oligomer (Figures 4B–4D and 4F–4H). The molecular mass of MASP-1 3D was 74 ± 2 kDa, and that for MASP-2 3D was 65 ± 2 kDa, in good agreement with sequence-calculated masses of 75 kDa for MASP-1 3D and 74 kDa for MASP-2 3D. That for zymogen MASP-1 was 163 ± 6 kDa, activated MASP-1 was 158 ± 6 kDa, zymogen MASP-2 was 147 ± 6 kDa, and activated MASP-2 was 166 ± 1 kDa. These values agreed well with the sequence-predicted masses of 170 kDa and 163 kDa for full-length MASP-1 and MASP-2 dimers, respectively. The sedimentation coefficient s20,w provided an independent measure of macromolecular elongation. The s20,w values of MASP-1 3D and MASP-2 3D were 4.53 S and 4.09 S, respectively (Table 2). The s20,w values of zymogen and activated MASP-1 were 5.90 S and 5.79 S, respectively, and those for zymogen and activated MASP-2 were 5.42 S and 5.62 S, respectively (Table 2). The s20,w value for MASP-2 3D was similar to that of 4.55 ± 0.10 S reported previously (Feinberg et al., 2003).
The availability of initial models or structures for MASP permitted comparison of the experimental s20,w values with those predicted from these. The precision of the comparisons is ±0.21 S (Perkins et al., 2016). Interestingly, the prediction of 4.26 S from the MASP-1 3D crystal structure was similar to the observed value of 4.53 ± 0.08, while that of 4.18 S from the MASP-2 crystal structure was close to the observed value of 4.09 ± 0.07 S (Table 2). The solution structures of both proteins thus broadly resembled those seen by crystallography (Figures 2A and 2B). In distinction, for the zymogen and activated forms of MASP-1 and MASP-2, these comparisons showed deviations from the initial models. For the full-length MASPs, the initial predictions of 5.38 S, 5.50 S, 5.28 S, and 5.28 S (Figures 4C, 4D, 4G, and 4H) were lower than the observed values of 5.90 ± 0.15 S, 5.79 ± 0.13 S, 5.42 ± 0.15 S, and 5.62 ± 0.16 S, respectively (Table 2), indicating that the solution structures were more bent than the initial extended homology models. This evidence for more compact structures indicated flexibility in the MASP-1 and MASP-2 structures that had not been previously recognized.
Atomistic Scattering Modeling of Rat MASPs
As for rat MBL (Miller et al., 2012), atomistic modeling for the six MASPs assessed whether the two linear MASP 3D crystal structures and four linear homology models for full-length MASP agreed with the experimental SAXS data. The predicted Rg values of 3.62 nm and 3.58 nm from the MASP-1 3D and MASP-2 3D crystal structures were less than but similar to the observed Rg values of 3.79 ± 0.01 nm and 3.87 ± 0.02 nm (Table 2; Figures 5A and 5D) to indicate that their solution structures broadly resembled their crystal structures (Figures 2A and 2B). In contrast, the linear homology models of zymogen and activated full-length MASP-1 gave predicted Rg values of 9.00 nm and 8.68 nm that were 10–13% greater than the observed Rg values of 7.93 ± 0.09 nm and 7.86 ± 0.12 nm (Table 2; Figures 5B and 5C). The predicted Rg values of 8.36 nm and 8.23 nm for the initial models of zymogen and activated full-length MASP-2 were likewise 9–10% greater than the observed Rg values of 7.58 ± 0.13 nm and 7.54 ± 0.04 nm (Table 2; Figures 5E and 5F). These Rg differences show that the full-length proteins in solution were more bent and compact in shape than the linear initial models, in agreement with the modeling of the s20,w values.
To identify detailed 3D solution structures, atomistic modeling searches were performed (Perkins et al., 2016). The MASP 3D crystal structures were used to generate physically realistic structures. Regions of flexibility were assigned to the EGF-CUB2 linkers and C-terminal hexaHis tags (Figure 1). The CUB1-EGF dimer contacts did not allow flexibility at the CUB1-EGF linker. Using a Monte Carlo procedure, the EGF-CUB2 linker peptides were randomized to generate 1,982–4,517 trial MASP 3D structures for computing their SAXS curves. A large improvement in the goodness-of-fit R factor to 4.8%–7.4% was obtained, compared with 9.2%–11.2% for the two crystal structures (Figures 5A and 5D). This decrease showed that the use of flexible EGF-CUB2 linkers resulted in significantly improved curve fits (Figures 6A and 6D). When two N-glycan oligosaccharides in extended conformations were added to the structures, the agreement between the experimental and calculated I(Q) and P(r) curves improved to R factors of 4.1%–4.2% (Figures 6A and 6D). All ten best-fit structures retain this conformational feature, being bent inward toward the center of the MASP 3D dimer (Figures 7A and 7D). When the degree of bending was parameterized (Figure S2A), the separation of 9.8–10.0 nm between the centers of the CUB2 domains in the two crystal structures was almost unchanged at 9.5 ± 0.5 nm in the ten best-fit models for MASP-1 3D and MASP-2 3D, while the angle between the two CUB2 domains was significantly decreased from 171° to as low as 142 ± 8° (Table S1). As an independent check of the modeling, the predicted s20,w values from the ten best-fit models for each of MASP-1 3D and MASP-2 3D gave mean values of 4.25 ± 0.07 S and 3.96 ± 0.03 S. These were similar to the experimental s20,w values of 4.53 ± 0.08 S and 4.09 ± 0.07 S, as for the two crystal structures (Figures 2A and 2B). In conclusion, while our atomistic modeling revealed similar extended MASP 3D structures in solution and in the crystal, the final SAXS models indicated large differences in the two 3D structures in which the CUB2 domains were bent right back, as much as vertically upward from the plane of the CUB1-EGF domains (Figures 6A, 6D, 7A, and 7D). Importantly for function, these differences suggest that the EGF-CUB2 junction is a flexible hinge with a 90° flex (Figure S2 and Table S1).
Atomistic SAXS modeling was also performed for full-length MASPs using the linear homology models to generate physically realistic varied structures. Flexible regions were assigned at the EGF-CUB2, CUB2-SCR1, SCR1-SCR2, and SCR2-SP linkers and the N-terminal hexaHis tags. The MASP 3D crystal structure was used in this. By a Monte Carlo procedure, the five linker peptides were varied to generate 6,173–30,910 trial MASP structures. The resulting goodness-of-fit R factors versus Rg values (Figures 5B, 5C, 5E, and 5F) showed that the linear homology model R factor values of 7.7%–9.1% were reduced to 6.5%–7.1% for the best-fit models. In addition, the best-fit models showed better agreements between the experimental and modeled Rg values. Bends in the four inter-domain linkers thus resulted in improved curve fits (Figures 6B, 6C, 6E, and 6F). When three N-glycosylation oligosaccharides were added to the MASP structures (Figure 1), the R factors were improved further to 4.6%–5.2% (Figures 6B, 6C, 6E, and 6F). Increasing the number of trial models showed no further improvement in R factors. A control Search 2 started from the best-fit scattering models for MASP 3D and not their crystal structures and gave unchanged R factors of 4.2%–5.8% (Figures 5B, 5C, 5E, 5F, 6B, 6C, 6E, and 6F). In summary, the ten best-fit scattering structures showed that the SP domains at the extremities of the dimer move toward each other to create bent structures (Figures 7B, 7C, 7E, and 7F).
The extent of bend in the final full-length MASP-1 and MASP-2 models was parameterized (Figure S2B). The initial separation of 27–29 nm (MASP-1) and 24–25 nm (MASP-2) between the SP domains in the starting models was reduced to 20–22 nm (MASP-1) and 16–20 nm (MASP-2) in the ten best-fit models (Table S1). While the two zymogens may be more compact than the two activated MASPs, any difference was small. The θ3 angles between the two SP domains decreased from 166°–172° in the starting models to 100°–142° (Table S1). As an independent check of the modeling, the predicted s20,w values from the ten best-fit models for zymogen and activated MASP-1 gave mean values of 5.92 S and 5.92 S, and those for zymogen MASP-2 and activated MASP-2 were 5.69 S and 5.61 S. These agreed better with the experimental s20,w value of 5.90 S, 5.79 S, 5.42 S, and 5.62 S in that order (Table 2) than the initial predictions (see above). In conclusion, we have demonstrated bent and flexible MASP-1 and MASP-2 structures in which the two SP domains are closer together.
Discussion
Our crystal structures and X-ray scattering data for six rat MASPs revealed a novel understanding of their solution structures and in particular on their flexibility. We report new experimental structures for intact full-length MASP-1 and MASP-2 and the first identification of flexible junctions between the MASP domains. The SAXS data were supported by ultracentrifugation and atomistic scattering modeling, showing that the full-length MASP solution structures are significantly bent. The EGF-CUB2 junction appeared highly flexible with up to 90° of flex (Figure 7). The combination of these bent and flexible MASP solution structures with our earlier model for an extended planar and flexible MBL structure (Miller et al., 2012) clarifies how the MASP and MBL structures interact with each other to activate the lectin pathway.
Flexibility of the MASP Domain Structures
The domain flexibility in MASPs is complementary to that deduced previously for MBL. Evidence for MASP flexibility comes from (1) the differences between the experimental sedimentation coefficients and the predictions from the initial linear MASP structures (Figures 4B–4D and 4F–4H) and (2) the large deviations between the initial linear MASP structures and its experimental X-ray scattering curve. Flexibility between CUB2 and SCR1 had previously been proposed in the formation of a “closed” MASP structure in which the two SCR1-SCR2-SP moieties and the CUB1-EGF-CUB2 moiety were hypothesized to form the three sides of a triangular domain arrangement that enabled the auto-activation of the SP domains (Feinberg et al., 2003, Teillet et al., 2008). Flexibility between the EGF and CUB2 domains was also hypothesized to be part of an activation mechanism for the MASP-MBL complex based on a CUB2-collagen crystal structure (Gingras et al., 2011). Differences of up to 90° between the linear crystal structures and the bent solution structures described here indicate that the EGF-CUB2 junction must be particularly flexible (Figure 7). A previous structural model for full-length MASP-1 based on a crystal structure for the four domains of MAP-1 (Skjoedt et al., 2012) is now seen to be too elongated and rigid when this is compared to the views in Figure 7. MASP flexibility was not considered in detail in a recent SAXS analysis in which 2-fold C2 symmetry was assumed in extended MASP dimer models that were fitted to the data (Kjaer et al., 2015). The current study has now provided clear evidence of MASP flexibility. The importance of bending relates to MASP auto-activation. The extent of bending observed in our best-fit MASP models may permit the two SP domains to come into contact with each other. Although this mechanism is not clearly proven by our present analyses, it cannot be excluded, as was suggested by another recent analysis (Kjaer et al., 2015).
In our previous SAXS structural modeling of MBL, flexibility was deduced from a bend observed between the CRD/neck region and the linear collagen region (Miller et al., 2012). This implies that the 9–12 CRD domains found in MBL trimers and tetramers are able to adjust their orientations and dock to a mannose-coated surface, irrespectively of the roughness of this surface. Each single CRD-mannose interaction has a low affinity, with a KD of about 1 mM; multiple CRD binding increases the affinity by several orders of magnitude.
Complexes between MASP and MBL
Recent crystal structures for the CUB1 and CUB2 domains of C1s and MASP-2 bound to the collagen triple helices of C1q and MBL, respectively, clarify how the MASP-MBL complexes are formed (Gingras et al., 2011, Venkatraman Girija et al., 2013). The superimposition of these two CUB-collagen structures with our MASP-1 and MASP-2 3D crystal structures (Figures 2A and 2B) provides a complete picture of the MASP-MBL complex (Figure 8). The 61-Hyp-Gly-Lys-Leu-Gly-Pro-66 motif within the collagen triple helix of rat MBL forms the binding site for MASP-2 (Wallis et al., 2004). Common to both the CUB1-collagen and CUB2-collagen interactions is Lys46 in the collagen helices, which interacts with three of the residues that coordinate the Ca2+ in each CUB domain. The firm identification in this study of the three Ca2+ sites in rat MASP-2 now resolves a key ambiguity of the earlier rat MASP-2 structure (Feinberg et al., 2003).
The combination of the MBL and MASP solution structures clarify how the MBL-MASP complex is formed:
-
(1)
Our atomistic solution structures for the MBL dimer, trimer, and tetramer showed near-planar oligomers (Miller et al., 2012). These possess a central hub from which the two, three, or four monomers fan outward and were consistent with EM and atomic force microscopy images of human MBL oligomers (Jensenius et al., 2009), which reported the most common angle between the MBL collagen monomers to be 47 ± 24°. This agreed well with our values of 63° for the dimer; 36° and 6° for the trimer; and 54°, 47°, and 51° for the tetramer (Miller et al., 2012). Because the angle between the collagen helices in our putative MASP-MBL complexes is about 70° (Figure 8), this angular similarity shows that MBL has a pre-formed collagen conformation that is able to interact with MASP via two of the four potential binding sites. Significant conformational changes of magnitude 10°–20°, however, would be required for simultaneous binding to three or four collagenous stems by the MBL trimers and tetramers.
-
(2)
Our flexible MASP structures revise our current understanding of the activation mechanism. Intra- or inter-molecular MASP mechanisms have been proposed and both have been inferred recently (Degn et al., 2013, Degn et al., 2014); however, there is no direct evidence for either mechanism because the changes that occur when complexes bind to a pathogen surface are not known. In the former, one-half of dimeric rat MASP-2 binds to at least two sites in a near-planar rat MBL structure, and MBL collagen flexibility is reduced when the CRD domains bind to a mannose-coated surface. This may stabilize the MASP-MBL interaction to trigger intra-molecular auto-activation between the two SP domains if they move closer together (Wallis, 2007). In the latter, if the MBL collagen regions form a “bunch-of-tulips” structure similar to that of the hexameric complement C1q structure, as often assumed (Degn et al., 2014), a MASP dimer could bind to all four stems within an MBL collagen cone. The SP domains in MASP will extend outward from such an MBL cone. This binding arrangement is supported by recent EM data of complexes between human MBL tetramers and MASP-1 dimers (Kjaer et al., 2015). That study also favored the inter-complex activation mechanism because it was suggested that MASP-1 polypeptides are not flexible enough to auto-activate based on SAXS and EM data. The findings described here, using SAXS combined with AUC and atomistic modeling, however, contradict this observation and show that both MASPs are much more flexible than previously thought. The observed flexibility suggests that the SP domains could bend toward each other within the complex to lead to intra-molecular MASP auto-activation upon binding to a mannose-coated surface. The choice between an intra- or inter-activation mechanism or a combination of both is presently unclear, in particular because it is not known what happens when MBL-MASP complexes bind to a pathogen surface. Certainly MASP flexibility highlighted by this present study, together with MBL flexibility, means that an intra-molecular MASP auto-activation model cannot be excluded.
-
(3)
Activation does not lead to large structural changes in the MASPs. Comparison of the zymogen and activated forms of MASP-1 and MASP-2 reveals little difference in the conformation or flexibility of MASP-1 or MASP-2. Instead, changes are presumably limited to the protease domain itself, as has been analyzed (Dobo et al., 2009, Gal et al., 2005).
Dimer Interface of the MASP Structures
A crucial issue for MASP function is the stability of the MASP dimer in physiological buffers. Although discussed for MASP crystal structures (Feinberg et al., 2003, Gregory et al., 2004), the observation of a crystallographic dimer does not prove that this dimer exists in solution. In this context, our AUC data showed the complete absence in solution of any monomer peaks at concentrations of 0.8–2.2 μM for full-length MASPs (Figure 4). These data indicate that the dimer dissociation constant KD will be at least 100-fold less at around 10 nM or less. This is consistent with MASP dimer formation at physiological concentrations of 65–70 nM (MASP-1) and 3–5 nM (MASP-2) in human plasma (Kjaer et al., 2015, Møller-Kristensen et al., 2003, Terai et al., 1997). Thus, the MASP dimers are stable in plasma. Stable dimers are characterized by a buried surface area in excess of 800 Å2 per molecule (Rupp, 2010). The large buried surface areas of the dimeric 3D crystal structures (Figures 2A and 2B) totaling 880–1,200 Å2 per molecule fully account for the existence of stable dimers in plasma.
Experimental Procedures
Production, Purification, and Crystallization of MASPs
All six rat MASPs and MASP fragments were produced and purified as described (Chen and Wallis, 2001, Wallis and Dodd, 2000). Rat MASP-1 and MASP-2 and their 3D fragments were produced in Chinese hamster ovary cells (Supplemental Information). The zymogens were enzymatically activated. All six proteins were purified by gel filtration chromatography on a Superdex 200 16/60 column (GE Healthcare) prior to crystallization or further analysis. SDS-PAGE was used to check the purity of all of the samples. The MASP 3D fragments were crystallized by the sitting drop method using the buffers specified in the Supplemental Information. X-ray diffraction data on four sets of crystals for MASP-1 and MASP-2 3D were collected at Leicester on a rotating copper anode source and at Diamond Light Source. Structures were determined by molecular replacement using the crystal structures of human MASP-1 (PDB: 3DEM) and rat MASP-2 (PDB: 1NT0) as search models. Details are provided in the Supplemental Information.
X-Ray Scattering and Analytical Ultracentrifugation
X-ray scattering curves I(Q) for MASP were acquired in two sessions on the BioSAXS robot at Instrument BM29 at the European Synchrotron Radiation Facility, Grenoble, France (Supplemental Information; Pernot et al., 2013, Round et al., 2015). The MASPs showed no radiation damage or X-ray induced aggregation in the time frame analyses. The time-averaged runs were thus used for data analyses to determine the radius of gyration Rg and Rxs values from Guinier plots and the distance distribution function P(r) curves. In AUC experiments, sedimentation velocity data were obtained on Beckman XL-I instruments equipped with AnTi50 rotors and using two-sector cells with column heights of 12 mm at a rotor speed of 50,000 rpm. The sedimentation coefficient distribution c(s) analyses fitted the absorbance scans directly to the Lamm equation, in which the sedimentation coefficient was determined from the peak position.
Determination of Solution Structures of MASP-1 and MASP-2
Starting models for all the MASP solution structures were generated from crystal structures. Based on earlier experience of atomistic modeling for dimers, 2-fold symmetry was not assumed for the MASP dimer modeling, and the models sampled both symmetric and asymmetric structures. Each structural model was subjected to two sets of conformational randomization at specified inter-domain linkers to generate broad ranges of trial structures for assessment. Likely flexible linkers between the six individual MASP domains and the His-tag in the starting structures are identified in bold (Figure 1)—two in the 3D proteins and five in the full-length MASPs. A dihedral angle Monte Carlo procedure was used to generate up to 30,000 domain conformations of the six MASPs using SASSIE (Perkins et al., 2016). Sterically overlapping poor models were discarded at their creation. Following this, the scattering curve simulations were performed with SCT (Wright and Perkins, 2015). The output was compared with the experimental X-ray scattering curves by using the calculated Guinier Rg and Rxs values and a goodness-of-fit R factor in order to identify the best-fit solution structures (Supplemental Information). As a further validation of the scattering modeling, sedimentation coefficients s020,w for each glycosylated best-fit model were calculated directly from the atomic coordinates using WinHydroPro v1.00, setting the radius of atomic elements as 0.284 nm in order to represent the hydrated structure (Ortega et al., 2011). Full details are described in the Supplemental Information.
Author Contributions
R.N. and R.W. designed and conducted the experiments, analyzed data, and contributed toward the writing. C.M.F. and J.G. conducted the experiments. R.N. and D.W.W. performed the modeling. S.J.P. designed and analyzed the experiments and wrote the manuscript. All authors edited the manuscript.
Acknowledgments
We thank Dr. Martha Brennich, Dr. Petra Pernot, and Dr. Adam Round at the ESRF in Grenoble, France for excellent instrumental support at BM29. We also thank beamline scientists at Diamond Light Source for their help with crystallographic data collection. R.N. was supported by an MRC grant (MR/K011715/1). D.W.W. was supported by the CCP-SAS project, a joint EPSRC (EP/K039121/1) and NSF (CHE-1265821) grant. R.W. is a member of the Midland Block Allocation Group for access to Diamond Light Source (allocation grants MX8359 and MX10369).
Published: January 19, 2017
Footnotes
Supplemental Information includes Supplemental Experimental Procedures, two figures, one table, and six pdb files and can be found with this article online at http://dx.doi.org/10.1016/j.str.2016.12.014.
Supplemental Information
References
- Botto M. C1q knock-out mice for the study of complement deficiency in autoimmune disease. Exp. Clin. Immunogenet. 1998;15:231–234. doi: 10.1159/000019076. [DOI] [PubMed] [Google Scholar]
- Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 2004;5:981–986. doi: 10.1038/ni1113. [DOI] [PubMed] [Google Scholar]
- Chen C.B., Wallis R. Stoichiometry of complexes between mannose-binding protein and its associated serine proteases. Defining functional units for complement activation. J. Biol. Chem. 2001;276:25894–25902. doi: 10.1074/jbc.M103539200. [DOI] [PubMed] [Google Scholar]
- Cole J.L., Lary J.W., P Moody T., Laue T.M. Analytical ultracentrifugation: sedimentation velocity and sedimentation equilibrium. Methods Cell Biol. 2008;84:143–179. doi: 10.1016/S0091-679X(07)84006-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Degn S.E., Jensen L., Olszowski T., Jensenius J.C., Thiel S. Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44. J. Immunol. 2013;191:1334–1345. doi: 10.4049/jimmunol.1300780. [DOI] [PubMed] [Google Scholar]
- Degn S.E., Kjaer T.R., Kidmose R.T., Jensen L., Hansen A.G., Tekin M., Jensenius J.C., Andersen G.R., Thiel S. Complement activation by ligand-driven juxtaposition of discrete pattern recognition complexes. Proc. Natl. Acad. Sci. USA. 2014;111:13445–13450. doi: 10.1073/pnas.1406849111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dobo J., Harmat V., Beinrohr L., Sebestyen E., Zavodszky P., Gal P. MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. J. Immunol. 2009;183:1207–1214. doi: 10.4049/jimmunol.0901141. [DOI] [PubMed] [Google Scholar]
- Feinberg H., Uitdehaag J.C., Davies J.M., Wallis R., Drickamer K., Weis W.I. Crystal structure of the CUB1-EGF-CUB2 region of mannose-binding protein associated serine protease-2. EMBO J. 2003;22:2348–2359. doi: 10.1093/emboj/cdg236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gal P., Harmat V., Kocsis A., Bian T., Barna L., Ambrus G., Vegh B., Balczer J., Sim R.B., Naray-Szabo G., Zavodszky P. A true autoactivating enzyme. Structural insight into mannose-binding lectin-associated serine protease-2 activations. J. Biol. Chem. 2005;280:33435–33444. doi: 10.1074/jbc.M506051200. [DOI] [PubMed] [Google Scholar]
- Gingras A.R., Girija U.V., Keeble A.H., Panchal R., Mitchell D.A., Moody P.C., Wallis R. Structural basis of mannan-binding lectin recognition by its associated serine protease MASP-1: implications for complement activation. Structure. 2011;19:1635–1643. doi: 10.1016/j.str.2011.08.014. [DOI] [PubMed] [Google Scholar]
- Gregory L.A., Thielens N.M., Arlaud G.J., Fontecilla-Camps J.C., Gaboriaud C. X-ray structure of the Ca2+-binding interaction domain of C1s. Insights into the assembly of the C1 complex of complement. J. Biol. Chem. 2003;278:32157–32164. doi: 10.1074/jbc.M305175200. [DOI] [PubMed] [Google Scholar]
- Gregory L.A., Thielens N.M., Matsushita M., Sorensen R., Arlaud G.J., Fontecilla-Camps J.C., Gaboriaud C. The X-ray structure of human mannan-binding lectin-associated protein 19 (MAp19) and its interaction site with mannan-binding lectin and L-ficolin. J. Biol. Chem. 2004;279:29391–29397. doi: 10.1074/jbc.M402687200. [DOI] [PubMed] [Google Scholar]
- Harmat V., Gal P., Kardos J., Szilagyi K., Ambrus G., Vegh B., Naray-Szabo G., Zavodszky P. The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme-substrate interactions. J. Mol. Biol. 2004;342:1533–1546. doi: 10.1016/j.jmb.2004.07.014. [DOI] [PubMed] [Google Scholar]
- Heja D., Kocsis A., Dobo J., Szilagyi K., Szasz R., Zavodszky P., Pal G., Gal P. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc. Natl. Acad. Sci. USA. 2012;109:10498–10503. doi: 10.1073/pnas.1202588109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hurwitz S. Homeostatic control of plasma calcium concentration. Crit. Rev. Biochem. Mol. Biol. 1996;31:41–100. doi: 10.3109/10409239609110575. [DOI] [PubMed] [Google Scholar]
- Iwaki D., Kanno K., Takahashi M., Endo Y., Matsushita M., Fujita T. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J. Immunol. 2011;187:3751–3758. doi: 10.4049/jimmunol.1100280. [DOI] [PubMed] [Google Scholar]
- Jensenius H., Klein D.C., van Hecke M., Oosterkamp T.H., Schmidt T., Jensenius J.C. Mannan-binding lectin: structure, oligomerization, and flexibility studied by atomic force microscopy. J. Mol. Biol. 2009;391:246–259. doi: 10.1016/j.jmb.2009.05.083. [DOI] [PubMed] [Google Scholar]
- Kidmose R.T., Laursen N.S., Dobo J., Kjaer T.R., Sirotkina S., Yatime L., Sottrup-Jensen L., Thiel S., Gal P., Andersen G.R. Structural basis for activation of the complement system by component C4 cleavage. Proc. Natl. Acad. Sci. USA. 2012;109:15425–15430. doi: 10.1073/pnas.1208031109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kjaer T.R., Le le T.M., Pedersen J.S., Sander B., Golas M.M., Jensenius J.C., Andersen G.R., Thiel S. Structural insights into the initiating complex of the lectin pathway of complement activation. Structure. 2015;23:342–351. doi: 10.1016/j.str.2014.10.024. [DOI] [PubMed] [Google Scholar]
- Miller A., Phillips A., Gor J., Wallis R., Perkins S.J. Near-planar solution structures of mannose-binding lectin oligomers provide insight on the activation of the lectin pathway of complement. J. Biol. Chem. 2012;287:3930–3945. doi: 10.1074/jbc.M111.320341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Møller-Kristensen M., Thiel S., Hansen A.G., Jensenius J.C. On the site of C4 deposition upon complement activation via the mannan-binding lectin pathway or the classical pathway. Scand. J. Immunol. 2003;57:556–561. doi: 10.1046/j.1365-3083.2003.01270.x. [DOI] [PubMed] [Google Scholar]
- Ortega A., Amoros D., Garcia de la Torre J. Prediction of hydrodynamic and other solution properties of rigid proteins from atomic- and residue-level models. Biophys. J. 2011;101:892–898. doi: 10.1016/j.bpj.2011.06.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perkins S.J., Nan R., Li K., Khan S., Abe Y. Analytical ultracentrifugation combined with X-ray and neutron scattering: experiment and modelling. Methods. 2011;54:181–199. doi: 10.1016/j.ymeth.2011.01.004. [DOI] [PubMed] [Google Scholar]
- Perkins S.J., Wright D.W., Zhang H., Brookes E.H., Chen J., Irving T.C., Krueger S., Barlow D.J., Edler K.J., Scott D.J. Atomistic modelling of scattering data in the collaborative computational project for small angle scattering (CCP-SAS) J. App. Crystallogr. 2016;49:1861–1875. doi: 10.1107/S160057671601517X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pernot P., Round A., Barrett R., De Maria Antolinos A., Gobbo A., Gordon E., Huet J., Kieffer J., Lentini M., Mattenet M. Upgraded ESRF BM29 beamline for SAXS on macromolecules in solution. J. Synch. Radiat. 2013;20:660–664. doi: 10.1107/S0909049513010431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Porter R.R., Reid K.B.M. The biochemistry of complement. Nature. 1978;275:699–704. doi: 10.1038/275699a0. [DOI] [PubMed] [Google Scholar]
- Round A., Felisaz F., Fodinger L., Gobbo A., Huet J., Villard C., Blanchet C.E., Pernot P., McSweeney S., Roessle M. BioSAXS Sample Changer: a robotic sample changer for rapid and reliable high-throughput X-ray solution scattering experiments. Acta Crystallogr. D Biol. Crystallogr. 2015;71:67–75. doi: 10.1107/S1399004714026959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rupp B. Garland Science; 2010. Biomolecular Crystallography: Principle, Practice and Application to Structural Biology. [Google Scholar]
- Schwaeble W.J., Lynch N.J., Clark J.E., Marber M., Samani N.J., Ali Y.M., Dudler T., Parent B., Lhotta K., Wallis R. Targeting of mannan-binding lectin-associated serine protease-2 (Masp2) confers a significant degree of protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA. 2011;108:7523–7528. doi: 10.1073/pnas.1101748108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Skjoedt M.O., Hummelshoj T., Palarasah Y., Honore C., Koch C., Skjodt K., Garred P. A novel mannose-binding lectin/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation. J. Biol. Chem. 2012;285:8234–8243. doi: 10.1074/jbc.M109.065805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stengaard-Pedersen K., Thiel S., Gadjeva M., Moller-Kristensen M., Sorensen R., Jensen L.T., Sjoholm A.G., Fugger L., Jensenius J.C. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N. Engl. J. Med. 2003;349:554–560. doi: 10.1056/NEJMoa022836. [DOI] [PubMed] [Google Scholar]
- Takahashi M., Ishida Y., Iwaki D., Kanno K., Suzuki T., Endo Y., Homma Y., Fujita T. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J. Exp. Med. 2010;207:29–37. doi: 10.1084/jem.20090633. S21–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Taylor P.R., Carugati A., Fadok V.A., Cook H.T., Andrews M., Carroll M.C., Savill J.S., Henson P.M., Botto M., Walport M.J. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 2000;192:359–366. doi: 10.1084/jem.192.3.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Teillet, F., Gaboriaud, C., Martin, L., Lacroix, M., Ogbi, S., Fontecilla-Camps, J.C., Arlaud, G.J., and Thielens, N.M.. (2006). The CUB1-EGF-CUB2 interaction domain of human MASP-3: X-ray structure and identification of its binding sites for MBL and L- and H-ficolins. In Proceedings of the VIth International Workshop on the First Component of Complement, C1 and Collectins. Seeheim, Germany, 15.
- Teillet F., Gaboriaud C., Lacroix M., Martin L., Arlaud G.J., Thielens N.M. Crystal structure of the CUB1-EGF-CUB2 domain of human MASP-1/3 and identification of its interaction sites with mannan-binding lectin and ficolins. J. Biol. Chem. 2008;283:25715–25724. doi: 10.1074/jbc.M803551200. [DOI] [PubMed] [Google Scholar]
- Terai I., Kobayashi K., Matsushita M., Fujita T. Human serum mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1): determination of levels in body fluids and identification of two forms in serum. Clin. Exp. Immunol. 1997;110:317–323. doi: 10.1111/j.1365-2249.1997.tb08334.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Turner M.W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol. Today. 1996;17:532–540. doi: 10.1016/0167-5699(96)10062-1. [DOI] [PubMed] [Google Scholar]
- Venkatraman Girija U., Gingras A.R., Marshall J.E., Panchal R., Sheikh M.A., Gal P., Schwaeble W.J., Mitchell D.A., Moody P.C.E., Wallis R. Structural basis of the C1q/C1s interaction and its central role in assembly of the C1 complex of complement activation. Proc. Natl. Acad. Sci. USA. 2013;110:13916–13920. doi: 10.1073/pnas.1311113110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wallis R. Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway. Immunobiology. 2007;212:289–299. doi: 10.1016/j.imbio.2006.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wallis R., Drickamer K. Molecular determinants of oligomer formation and complement fixation in mannose-binding proteins. J. Biol. Chem. 1999;274:3580–3589. doi: 10.1074/jbc.274.6.3580. [DOI] [PubMed] [Google Scholar]
- Wallis R., Dodd R.B. Interaction of mannose-binding protein with associated serine proteases: effects of naturally occurring mutations. J. Biol. Chem. 2000;275:30962–30969. doi: 10.1074/jbc.M004030200. [DOI] [PubMed] [Google Scholar]
- Wallis R., Shaw J.M., Uitdehaag J., Chen C.B., Torgersen D., Drickamer K. Localization of the serine protease-binding sites in the collagen-like domain of mannose-binding protein: indirect effects of naturally occurring mutations on protease binding and activation. J. Biol. Chem. 2004;279:14065–14073. doi: 10.1074/jbc.M400171200. [DOI] [PubMed] [Google Scholar]
- Wallis R., Dodds A.W., Mitchell D.A., Sim R.B., Reid K.B., Schwaeble W.J. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway. J. Biol. Chem. 2007;282:7844–7851. doi: 10.1074/jbc.M606326200. [DOI] [PubMed] [Google Scholar]
- Wallis R., Mitchell D.A., Schmid R., Schwaeble W.J., Keeble A.H. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology. 2010;215:1–11. doi: 10.1016/j.imbio.2009.08.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wright D.W., Perkins S.J. SCT: a suite of programs for comparing atomistic models with small-angle scattering data. J. App. Crystallogr. 2015;48:953–961. doi: 10.1107/S1600576715007062. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.